Document:

Exhibit 10.46

 

AMENDMENT TO LICENSE AGREEMENT

 

THIS AMENDMENT
TO LICENSE AGREEMENT (this “Amendment”) is made as of the 19th day of December,
2008, by and between Artann Laboratories, Inc. (“Artann”), a
New Jersey corporation and ProUroCare Medical, Inc. (“ProUroCare”), a
Nevada corporation.

 

RECITALS

 

A.                                   Artann
and ProUroCare entered into a license agreement on July 25, 2008 relating
to a prostate mechanical imaging system (“the License Agreement”).

 

B.                                     The
parties now wish to amend the License Agreement as provided herein.

 

Now,
therefore, in consideration of the covenants and agreements set forth herein
and for valuable consideration, receipt of which is hereby acknowledged, the
parties mutually agree as follows:

 

AGREEMENT

 

ARTICLE I

DEFINITIONS

 

Terms used in
this Amendment but not defined or redefined in this Amendment have the meanings
ascribed thereto in the License Agreement.

 

ARTICLE II

AMENDMENTS

 

2.1                                 Effective Date.  The definition of “Effective Date” set forth
in Section 1.1 of the License Agreement shall be amended and restated to
read in its entirety as follows:

 

“Effective
Date” means December 23, 2008.

 

2.2                                 Artann.  The reference to Artann as being a Delaware
corporation in the introductory paragraph of the License Agreement shall be
corrected to refer to Artann as a New Jersey corporation.

 

2.3                                 Payees.  A new Section 3.11 of the License
Agreement shall be added which shall read in its entirety as follows:

 

3.11 Payees.  It is understood that Armen Sarvazyan (“Sarvazyan”)
and Vladamir Egorov (“Egorov”) were significantly involved in development
activities associated with the PMI System. 
Artann desires that a portion of the payments due it under this Article 3
be made to Sarvazyan and another portion be made to Egorov with 

 

1

 

the remainder
being made to Artann.  ProUroCare hereby
agrees to make and shall make each and any such payment due Artann under this Article 3
to Sarvazyan, Egorov and Artann in the percentages specified and directed by
Artann pursuant a notice provided pursuant to Section 7.9; provided,
however, that the total amount of each such payment to be made by ProUroCare
shall remain unchanged.

 

IN WITNESS
THEREOF, the parties, intending to be legally bound, have caused this Amendment
to be executed by their duly authorized officers, as of the effective date of
this Amendment.

 

	
  PROUROCARE
  MEDICAL, INC.

  	
  ARTANN
  LABORATORIES, INC.

  
	
   

  	
   

  
	
   

  	
   

  
	
  By:

  	
  /s/ Richard Carlson

  	
   

  	
  By:

  	
  /s/ Noune Sarvazyan

  
	
   

  	
   

  
	
   

  	
   

  	
   

  
	
  (Print or
  Type Name)

  	
  (Print or
  Type Name)

  
	
   

  	
   

  
	
  Title:

  	
  CEO

  	
   

  	
  Title:

  	
  CEO

  
									

 

2Exhibit 10.47

 

AMENDMENT TO DEVELOPMENT AND
COMMERCIALIZATION AGREEMENT

 

THIS AMENDMENT
TO DEVELOPMENT AND COMMERCIALIZATION AGREEMENT (this “Amendment”) is made as of
the 19th day of December, 2008, by and between Artann Laboratories, Inc.
(“Artann”), a New Jersey corporation and ProUroCare Medical, Inc. (“ProUroCare”),
a Nevada corporation.

 

RECITALS

 

A.                                   Artann
and ProUroCare entered into a development and commercialization agreement on July 25,
2008 relating to a prostate mechanical imaging system (“the Development and
Commercialization Agreement”).

 

B.                                     The
parties now wish to amend the Development and Commercialization Agreement as
provided herein.

 

Now,
therefore, in consideration of the covenants and agreements set forth herein
and for valuable consideration, receipt of which is hereby acknowledged, the
parties mutually agree as follows:

 

AGREEMENT

 

ARTICLE I

DEFINITIONS

 

Terms used in
this Amendment but not defined or redefined in this Amendment have the meanings
ascribed thereto in the Development and Commercialization Agreement.

 

ARTICLE II

AMENDMENTS

 

2.1                                 Effective Date.  The definition of “Effective Date” set forth
in Section 1.1 of the Development and Commercialization Agreement shall be
amended and restated to read in its entirety as follows:

 

“Effective
Date” means December 23, 2008.

 

2.2                                 Artann.  The reference to Artann as being a Delaware
corporation in the introductory paragraph of the License Agreement shall be
corrected to refer to Artann as a New Jersey corporation.

 

2.3                                 Payees.  A new Section 3.6 of the Development and
Commercialization Agreement shall be added which shall read in its entirety as
follows:

 

1

 

3.6                                 Payees.  It is understood that Armen Sarvazyan (“Sarvazyan”)
and Vladamir Egorov (“Egorov”) were significantly involved in development
activities associated with the PMI System. 
Artann desires that a portion of the payments due it under this Article 3
be made to Sarvazyan and another portion be made to Egorov with the remainder
being made to Artann.  ProUroCare hereby
agrees to make and shall make each and any such payment due Artann under this Article 3
to Sarvazyan, Egorov and Artann in the percentages specified and directed by
Artann pursuant to a notice provided pursuant Section 9.9; provided,
however, that the total amount of each such payment to be made by ProUroCare
shall remain unchanged.

 

IN WITNESS
THEREOF, the parties, intending to be legally bound, have caused this Amendment
to be executed by their duly authorized officers, as of the effective date of
this Amendment.

 

	
  PROUROCARE
  MEDICAL, INC.

  	
  ARTANN
  LABORATORIES, INC.

  
	
   

  	
   

  
	
   

  	
   

  
	
  By:

  	
  /s/ Richard Carlson

  	
   

  	
  By:

  	
  /s/ Noune Sarvazyan

  
	
   

  	
   

  
	
   

  	
   

  	
   

  
	
  (Print or
  Type Name)

  	
  (Print or
  Type Name)

  
	
   

  	
   

  
	
  Title:

  	
  CEO

  	
   

  	
  Title:

  	
  CEO

  
									

 

2Exhibit 10.5

 

THE
TORO COMPANY

 

2000
STOCK OPTION PLAN

 

(As
Amended December 3, 2008)

 

1.                                       Purpose. The
purpose of The Toro Company 2000 Stock Option Plan (the “Plan”) is to enhance
stockholder value of The Toro Company (the “Company”) by providing an incentive
to key employees and other key individuals who perform services for the Company
to contribute significantly to the long-term performance and growth of the
Company; to link a significant portion of a participant’s compensation to the
value of the Company’s Common Stock, par value $1.00 per share (“Common Stock”);
and to attract and retain experienced and knowledgeable employees on a
competitive basis. These purposes are expected to be achieved by granting
options to acquire the Common Stock (“options”).

 

2.                                       Eligibility.
Any employee of the Company who is regularly employed in an executive,
managerial, professional or technical position and any other individual who
performs services for the Company and who contributes significantly to the
strategic and long-term performance objectives of the Company is eligible to
participate in the Plan. Options may be granted to directors of the Company who
are also employees of the Company. More than one option may be granted to the
same individual.

 

a.                                       Limitations.
No option may be granted to an individual who owns, directly or indirectly,
Common Stock or other capital stock of the Company possessing more than 5% of
the total combined voting power or value of any class of capital stock of the
Company or a subsidiary immediately after such option is granted, and the
maximum number of shares that may be covered by options granted to any
individual during any calendar year shall be 100,000 shares. Except for the
foregoing limitations, there is no minimum or maximum number of shares of
Common Stock with respect to which options may be granted to any individual
under the Plan. Individuals to whom options are granted are referred to as “option
holders”.

 

3.                                       Stock Options.

 

a.                                       ISOs and Nonqualified Options. Options granted under the Plan may be either nonqualified stock
options (“nonqualified options”) or incentive stock options (“Incentive Stock
Options”) as defined in Section 422 of the Internal Revenue Code of 1986,
as amended (the “Code”).

 

(i)                                     Incentive Stock Options. Incentive Stock Options shall meet the applicable requirements
of, and contain or be deemed to contain all provisions required by, the Code or
corresponding provisions of subsequent revenue laws and regulations in effect
at the time such options are granted. Any ambiguities in construction shall be
interpreted in order 

 

 

to effectuate such intent. To the extent that
the aggregate fair market value of Common Stock (determined at the time of
grant of the Incentive Stock Option) with respect to which Incentive Stock
Options are exercisable for the first time by an option holder during any
calendar year (under all such plans of the Company and its parent and
subsidiary corporations) exceeds $100,000 or such other limit as may be imposed
by the Code, such options to the extent they exceed such limit shall be treated
as options which are not Incentive Stock Options. In applying the foregoing
limitation, options shall be taken into account in the order in which they were
granted.

 

b.                                      Agreements.
Options shall be evidenced by stock option agreements in such form and not
inconsistent with the Plan as the Compensation and Human Resources Committee
(the “Committee”) of the Board of Directors shall approve from time to time.

 

c.                                       Number of Shares, Date of Grant and Term. An option agreement shall specify the number of shares of Common
Stock to which it pertains; the date of grant, which shall be the date on which
the Committee grants an option or any later date which the Committee
specifically designates, and the term of the option, which shall not exceed ten
years.

 

d.                                      Exercise Price. The exercise price of an option shall be not less than 100% of
fair market value of the Common Stock on the date of grant. Fair market value
is the 4 p.m. Eastern Time closing price for the Common Stock as reported
by the New York Stock Exchange. Notwithstanding the foregoing, to the extent
that options are granted under the Plan as a result of the Company’s assumption
or substitution of options issued by any acquired, merged or consolidated entity,
the exercise price for such options shall be the price determined by the
Committee pursuant to the conversion terms applicable to the transaction. After
an option is granted, the exercise price shall not be reduced.

 

e.                                       Vesting, Transferability and Exercisability.

 

(i)                                     Vesting. An option granted to an officer, general manager or employee of
the Company shall vest and become exercisable in three approximately equal
installments on each of the first, second and third anniversaries after the
date of grant.  An option granted to an
other service provider who is not an officer, general manager or employee of
the Company shall vest and become exercisable in full on the second anniversary
after the date of grant.  Notwithstanding
the foregoing, the Committee shall have the authority to provide in any option
agreement for any one or more of the following:  (a) longer periods
after the date of grant during which an option or any portion thereof may not
yet be exercisable, (b) acceleration of vesting in the event of an option
holder’s disability or death and (c) continued vesting after an option
holder’s retirement, subject to Section 3.e(iii)(c).

 

2

 

(ii)                                  No Transfer. Options
shall not be transferable by the option holder except by will or applicable
laws of descent and distribution.

 

(iii)                               Exercise. During the lifetime of an option holder, an option may be
exercised only by the option holder and only while an employee of the Company
or a parent or subsidiary of the Company or otherwise performing services for
the Company or a parent or subsidiary and only if the option holder has been
continuously so employed or engaged since the date such options were granted,
except as the Committee may otherwise determine and provide for in an option
agreement at the time of grant or, if the Committee does not so provide, as
follows:

 

(a)                                  Disability.
In the event of disability of an option holder, options may be exercised by
such individual or his or her guardian or legal representative, not later than
the earlier of the date the option expires or one year after the date
employment or performance of services ceases by reason of such disability, but
only with respect to an option exercisable at the time employment or
performance of services ceases.

 

(b)                                 Death. An
option may be exercised after the death of an option holder only by such
individual’s legal representatives, heirs or legatees, not later than the
earlier of the date the option expires or one year after the date of death of such
individual, and only with respect to an option exercisable at the time of
death.

 

(c)                                  Retirement.
An option may be exercised by an option holder after such individual ceases to
be an employee by reason of retirement for up to four years after the date of
retirement but not later than the date the option expires, provided that the
option holder has remained an employee of the Company through the last day of
the fiscal year in which the option is granted. 
“Retirement” shall have the meaning established by the Committee from
time to time or, if no such meaning is established, shall mean termination of
employment with the Company at or after age 55 and with a number of years of
service that, when added together with the option holder’s age, equals at least
65.

 

(d)                                 Other Termination of Employment. An option may be exercised by an option holder after such
individual ceases to be an employee (for reasons other than disability, death
or retirement) for up to three months after the date of termination of employment
but not later than the date the option expires.

 

(iv)                              Non-compete. Notwithstanding any other provision of paragraph 3.e., if within
one year after the termination of employment with or performance of services
for the Company, an option holder is (a) employed or retained 

 

3

 

by or renders service to any organization
that, directly or indirectly, competes with or becomes competitive with the
Company, or if the rendering of such services is prejudicial or in conflict
with the interests of the Company, or (b) violates any confidentiality
agreement or agreement governing the ownership or assignment of intellectual
property rights with the Company, or (c) engages in any other conduct or
act determined to be injurious, detrimental or prejudicial to any interest of
the Company, the Company may cancel or rescind or restrict all options held by
such individual and shall have the right to the return of the economic value of
any option which was realized or obtained (measured at the date of exercise) by
such individual at any time during the period beginning on the date that is
twelve months prior to the date of termination to the date of the last
exercise, provided however, that this provision shall not be applicable in the
event of a Change of Control.

 

(v)                                 Interruption in Service. Absence on leave from the Company, or other interruption in the
performance of services, by an option holder shall, if approved by the
Committee, not be deemed a cessation or interruption of employment or services
for the purposes of the Plan.

 

f.                                         Methods of Exercise and Payment of
Exercise Price. Subject to the terms and
conditions of the Plan and the terms and conditions of the option agreement, an
option may be exercised in whole at any time or in part from time to time, by
delivery to the Company at its principal office of a written notice of exercise
specifying the number of shares with respect to which the option is being
exercised, accompanied by payment in full of the exercise price for shares to
be purchased at that time. Payment may be made (i) in cash, (ii) by
tendering (either actually or by attestation) shares of Common Stock already
owned for at least six months (or other period necessary to avoid a charge to
the Company’s earnings for financial statement purposes) valued at the fair
market value of the Common Stock on the date of exercise or (iii) in a
combination of cash and Common Stock; or the Committee may also, in its sole
discretion exercised either at the time the option is granted or at any time
before an option is exercised, (iv) permit option holders to deliver a
notice of exercise of options, together with irrevocable instructions, approved
in advance by proper officers of the Company, (A) to a brokerage firm
designated by the Company, to deliver promptly to the Company the aggregate
amount of sale or loan proceeds to pay the exercise price and any related tax
withholding obligations and (B) to the Company, to deliver certificates
for such purchased shares directly to such brokerage firm, all in accordance
with regulations of the Federal Reserve Board; or (v) authorize such other
methods as it deems appropriate and as comply with requirements of the Code,
the Securities Exchange Act of 1934 (the “Exchange Act”) and other applicable
laws and regulations. No shares of Common Stock shall be issued until full
payment has been made.

 

g.                                      Rights as a Stockholder. An option holder shall have no rights as a stockholder with
respect to any Common Stock covered by an option until the option is 

 

4

 

exercised and shares of Common Stock are
issued. Except as otherwise expressly provided in the Plan, no adjustments
shall be made for dividends or other rights for which the record date is prior
to issuance of the Common Stock.

 

4.                                       Common Stock Subject to the Plan. Subject to adjustment to reflect corporate transactions provided
for in paragraph 4.a., the total number of shares of Common Stock that is
reserved and available for issuance pursuant to options granted under the Plan
shall be 7,200,000. Any shares issued by the Company in connection with the
assumption or substitution of outstanding grants from any acquired corporation
shall not reduce the shares available for option grants under the Plan. Shares
of Common Stock that may be issued under the Plan may be authorized but
unissued shares, reacquired or treasury shares, or outstanding shares acquired
in the market or from private sources, or a combination thereof.  Shares of Common Stock that are issued under
the Plan or that are potentially issuable pursuant to outstanding options
granted under the Plan will be applied to reduce the maximum number of shares
of Common Stock remaining available for issuance under the Plan.  All shares so subtracted from the amount
available under the Plan with respect to an option that lapses, expires, is
forfeited or for any reason is terminated unexercised or unvested or is settled
or paid in cash or any form other than shares of Common Stock will not automatically
again become available for issuance under the Plan.  Without limiting the generality of the
foregoing, (i) any shares which would have been issued upon any exercise
of an option but for the fact that the exercise price was paid by the tender or
attestation as to ownership of shares of Common Stock already owned pursuant to
paragraph 3.f. of the Plan will not again become available for issuance under
the Plan, (ii) shares withheld or repurchased by the Company to satisfy
the payment of the exercise price of an option or any tax withholding
obligation will not again become available for issuance under the Plan, and (iii) shares repurchased
by the Company using option proceeds will not again become available for
issuance under the Plan.

 

a.                                       Adjustments for Corporate Transactions. In the event of a corporate transaction involving the Company
(including, without limitation, any merger, consolidation, recapitalization,
reorganization, split off, spin off, reclassification, combination, stock
dividend, stock split, reverse stock split, repurchase, exchange, extraordinary
cash dividend, issuance of warrants or other rights to purchase Common Stock or
other securities of the Company, or other similar corporate transaction or
change in the corporate structure of the Company affecting the Common Stock, or
a sale by the Company of all or part of its assets or any distribution to
stockholders other than a normal cash dividend), the Committee shall make such
proportional adjustments as are necessary to preserve the benefits or potential
benefits of the options. Action by the Committee may include appropriate
adjustments in all or any of (i) the number of shares of the Common Stock
or other new or different securities that may be available for option grants
under the Plan; (ii) the number of shares of Common Stock or other new or
different securities subject to outstanding options; (iii) the option
price per share of outstanding options and, if deemed appropriate, cash
payments; (iv) the maximum number and kind of securities that may be made
subject to options for any individual as set forth in paragraph 2.a.; or (v) any
other adjustment the Committee determines to be equitable. The Committee may
also, in its sole 

 

5

 

discretion, make provisions in any option
agreement for the protection of outstanding options in the event of such a
corporate transaction.

 

5.                                       Administration of the Plan.

 

a.                                       The Plan shall be administered by the Committee, provided that
members of the Committee shall be “non-employee directors” as contemplated by Rule 16b-3
under the Exchange Act or any successor rule and shall qualify to
administer the Plan as “outside directors” as contemplated by Section 162(m) of
the Internal Revenue Code and the regulations thereunder (“Section 162(m)”).
The Committee may delegate administrative duties and all decisions not required
to be exercised by it under Section 162(m), Section 16 of the
Exchange Act or the rules of the New York Stock Exchange to an officer of
the Company. The decision of the Committee on any matter affecting the Plan and
obligations arising under the Plan or any option granted thereunder shall be
deemed final and binding upon all persons, including the Company, its
stockholders and option holders. No member of the Board or of the Committee
shall be liable for any action taken or determination made in good faith with
respect to the Plan or any option granted under the Plan.

 

b.                                      Subject to the express provisions of the Plan, the Committee shall
have authority, in its discretion, to grant options; to interpret the Plan; to
prescribe, amend and rescind rules and regulations relating to the Plan;
to determine the exercise price of each option to purchase Common Stock, the
individuals to whom and the time or times at which options shall be granted,
the number of shares to be subject to each option, when an option may be
exercisable and the other terms and provisions (and amendments thereto) of the
respective option agreements (which need not be identical); to determine
whether a particular option is to be an Incentive Stock Option; and to make all
other determinations deemed necessary or advisable for the administration of
the Plan.

 

c.                                       Notwithstanding any other provision of this Plan other than paragraph
4, the Committee may not, without prior approval of the Company’s stockholders,
seek to effect any repricing of any previously granted option by: (i) amending
or modifying the terms of the option to lower the exercise price; (ii) canceling
the option and granting replacement options having a lower exercise price in
exchange; (iii) repurchasing the options and granting new options under
this Plan; or (iv) taking any other action that is treated as a “repricing”
under generally accepted accounting principles.

 

6.                                       Foreign Nationals and Residents of
California.

 

a.                                       Foreign Nationals. Without amending the Plan, options may be granted to individuals
who are foreign nationals or are employed or otherwise performing services for
the Company or any subsidiary outside the United States or both, on such terms
and conditions different from those specified in the Plan as may, in the 

 

6

 

judgment of the Committee, be necessary or
desirable to further the purposes of the Plan.

 

b.                                      California Residents. Without amending the Plan, and notwithstanding any provision of
the Plan to the contrary, options granted to individuals who are residents of
the State of California may contain such terms and conditions as may be
required by applicable California statutes governing stock options.

 

c.                                       Limitations. The
Committee shall have no authority, however, to take action pursuant to
paragraphs 6.a. and 6.b. of the Plan: (i) to reserve shares or grant
options in excess of the limitations provided in paragraph 4 of the Plan; (ii) to
effect any repricing in violation of paragraph 5.c. of the Plan; (iii) to
grant options having an exercise price in violation of paragraph 3.d. of the
Plan; or (iv) for which stockholder approval would then be required
pursuant to any applicable law, rule or regulation, including without
limitation the rules and regulations of the New York Stock Exchange and
the Securities and Exchange Commission.

 

7.                                       Change of Control. In the event of a Change of Control of the Company as hereinafter
defined, whether or not approved by the Board, all options shall fully vest,
unless otherwise limited by the Committee at the time of the option grant, and
be exercisable in their entirety immediately, and notwithstanding any other
provisions of the Plan, shall continue to be exercisable for three years
following the Change of Control, but not later than ten years after the date of
grant.

 

a.                                       Definition.
For the purpose of this paragraph 7, a “Change of Control” shall mean:

 

(i)                                     The acquisition by any individual, entity or group (within the
meaning of Section 13(d)(3) or 14(d)(2) of the Exchange Act) (a “Person”)
of beneficial ownership (within the meaning of Rule 13d-3 under the
Exchange Act) of 15% or more of either (A) the then-outstanding shares of
Common Stock of the Company (the “Outstanding Company Common Stock”) or (B) the
combined voting power of the then-outstanding voting securities of the Company
entitled to vote generally in the election of directors (the “Outstanding
Company Voting Securities”); provided, however, that for purposes of this
subsection (i), the following acquisitions shall not constitute a Change
of Control: (A) any acquisition directly from the Company, (B) any
acquisition by the Company, (C) any acquisition by any employee benefit
plan (or related trust) sponsored or maintained by the Company or any
corporation controlled by the Company, or (D) any acquisition by any
corporation pursuant to a transaction that complies with clauses (A), (B) and
(C) of subsection (iii) of this paragraph 7; or

 

(ii)                                  Individuals who, as of the date hereof, constitute the Board of
Directors of the Company (the “Incumbent Board”) cease for any reason to
constitute at least a majority of the Board; provided, however, that any
individual becoming a director subsequent to the date hereof whose election, or

 

7

 

nomination for election by the Company’s
stockholders, was approved by a vote of at least a majority of the directors
then comprising the Incumbent Board shall be considered as though such
individual were a member of the Incumbent Board, but excluding, for this
purpose, any such individual whose initial assumption of office occurs as a
result of an actual or threatened election contest with respect to the election
or removal of directors or other actual or threatened solicitation of proxies
or consents by or on behalf of a Person other than the Board; or

 

(iii)                               Consummation of a reorganization, merger or consolidation of the
Company or sale or other disposition of all or substantially all of the assets
of the Company or the acquisition by the Company of assets or stock of another
entity (a “Business Combination”), in each case, unless, following such
Business Combination, (A) all or substantially all of the individuals and
entities who were the beneficial owners, respectively, of the Outstanding
Company Common Stock and Outstanding Company Voting Securities immediately
prior to such Business Combination beneficially own, directly or indirectly,
more than 50% of, respectively, the then-outstanding shares of common stock and
the combined voting power of the then-outstanding voting securities entitled to
vote generally in the election of directors, as the case may be, of the
corporation resulting from such Business Combination (including, without
limitation, a corporation which as a result of such transaction owns the
Company or all or substantially all of the Company’s assets either directly or
through one or more subsidiaries) in substantially the same proportions as
their ownership, immediately prior to such Business Combination of the
Outstanding Company Common Stock and Outstanding Company Voting Securities, as the case may be, (B) no
Person (excluding any corporation resulting from such Business Combination or
any employee benefit plan (or related trust) of the Company or such corporation
resulting from such Business Combination) beneficially owns, directly or
indirectly, 15% or more of, respectively, the then-outstanding shares of common
stock of the corporation resulting from such Business Combination, or the
combined voting power of the then-outstanding voting securities of such
corporation except to the extent that such ownership existed prior to the
Business Combination and (C) at least a majority of the members of the
board of directors of the corporation resulting from such Business Combination
were members of the Incumbent Board at the time of the execution of the initial
agreement, or of the action of the Board, providing for such Business
Combination; or

 

(iv)                              Approval by the stockholders of the Company of a complete
liquidation or dissolution of the Company.

 

8.                                       Tax Withholding. The Company shall have the right to deduct from any settlement
made under the Plan, including the exercise of an option or the sale of shares
of Common Stock, any federal, state or local taxes of any kind required by law
to be withheld with 

 

8

 

respect to such payments or to require the
option holder to pay the amount of any such taxes or to take such other action
as may be necessary in the opinion of the Company to satisfy all obligations
for the payment of such taxes. If Common Stock is withheld or surrendered to
satisfy tax withholding, such stock shall be valued at its fair market value as
of the date such Common Stock is withheld or surrendered. The Company may also
deduct from any such settlement any other amounts due the Company by the option
holder.

 

9.                                       Governing Law.
The Plan, options granted under the Plan and agreements entered into under the
Plan shall be construed, administered and governed in all respects under and by
the applicable laws of the State of Delaware, excluding any conflicts or choice
of law rule or principle that might otherwise refer construction or
interpretation of the Plan or an agreement to the substantive law of another
jurisdiction.

 

10.                                 Plan Amendment and Termination. The Board may amend, suspend or terminate the Plan at any time,
with or without advance notice to option holders; provided however that no
amendment that would (a) increase the maximum number of shares that may be
subjected to options or (b) increase the number of shares that may be
covered by an option grant to any person referred to in Section 162(m) or
(c) modify requirements as to eligibility for participation in the Plan or
(d) constitute a material revision to the terms of the Plan within the
meaning of the rules and regulations of the New York Stock Exchange or the
Securities and Exchange Commission or (e) than is required by any
applicable law, rule or regulation to be approved by the stockholders of
the Company or (f) modify paragraph 3.d. or 5.c. of the Plan shall be
effective unless the stockholders of the Company shall have approved such
amendment in accordance with applicable provisions of the Code, other law, rule or
regulation. No amendment, modification or termination of the Plan may adversely
affect in a material manner any right of any option holder with respect to any
option theretofore granted without such option holder’s written consent.

 

11.                                 Effective Date and Duration of the Plan. The Plan first became effective on March 29, 2000. Any
amendment to the Plan shall be effective on the date established by the
Committee, subject to stockholder approval, if required. The Plan shall remain
in effect until all shares reserved for issuance pursuant to the Plan have been
purchased pursuant to options granted under the Plan, provided that options
under the Plan must be granted not later than ten years after the effective
date of the Plan or any future amendment approved by stockholders.

 

9

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00151-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00151-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00151-of-00352.parquet"}]]